Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10329434" target="_blank" >RIV/00179906:_____/16:10329434 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/16:10329434
Result on the web
<a href="http://dx.doi.org/10.2174/1568009616666160408150032" target="_blank" >http://dx.doi.org/10.2174/1568009616666160408150032</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/1568009616666160408150032" target="_blank" >10.2174/1568009616666160408150032</a>
Alternative languages
Result language
angličtina
Original language name
Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge
Original language description
Despite impressive therapeutic progress represented by the advent of chemoimmunotherapy, chronic lymphocytic leukemia (CLL) remains incurable by conventional modalities. Refractory CLL defined by non-response to treatment or relapse/progression within 6 months is associated with multiple unfavourable prognostic factors such as p53 pathway disruption, deteriorating patient condition, increased risk of severe infections, and poor response to treatment, resulting in a very short overall survival. Therefore, refractory CLL represents a highly challenging situation for the hematologist as well as the patient. The amount and quality of data on refractory CLL are rather limited as clinical trials usually combine patients with relapsed and refractory disease. Therapeutic options for refractory CLL include alemtuzumab, ofatumumab, fludarabine- and bendamustine-based regimens, platinum-based aggressive protocols and high-dose corticosteroids combined with monoclonal antibodies. The recent introduction of ibrutinib and idelalisib, small molecules interfering with B-cell receptor pathways, revolutionized the treatment of refractory CLL by the novel concept of long-term, oral treatment leading to impressive progression-free and overall survival improvement. Allogeneic stem cell transplantation is still considered the only option with curative potential. This review focuses on the currently available therapeutic strategies for refractory CLL.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT13412" target="_blank" >NT13412: Complex assessment of microenvironment and its impact on clinical course of chronic lymphocytic leukemia.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Cancer Drug Targets
ISSN
1568-0096
e-ISSN
—
Volume of the periodical
16
Issue of the periodical within the volume
8
Country of publishing house
AE - UNITED ARAB EMIRATES
Number of pages
9
Pages from-to
701-709
UT code for WoS article
000387003900006
EID of the result in the Scopus database
2-s2.0-84989259706